Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MAPT | P10636 | 1/20 | 0.49 |
| ▸ | S1PR1 | P21453 | 5/20 | 0.47 |
| ▸ | APP | P05067 | 10/20 | 0.39 |
| ▸ | NPC1 | O15118 | 2/20 | 0.39 |
| ▸ | PKM | P14618 | 2/20 | 0.39 |
| ▸ | RAB9A | P51151 | 2/20 | 0.39 |
| ▸ | GRM5 | P41594 | 1/20 | 0.39 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.39 |
| ▸ | HSP90AA1 | P07900 | 1/20 | 0.39 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.39 |
| ▸ | S1PR3 | Q99500 | 1/20 | 0.38 |
| ▸ | PDE10A | Q9Y233 | 1/20 | 0.38 |
| ▸ | ALOX5AP | P20292 | 1/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL21273251 | 0.89 | S1PR1 (0.53) | MAPTS1PR1NPC1PKMRAB9A | |
| SCHEMBL21273256 | 0.88 | S1PR1 (0.48) | MAPTS1PR1NPC1PKMRAB9A | |
| SCHEMBL21273259 | 0.84 | S1PR1 (0.48) | MAPTS1PR1NPC1PKMRAB9A | |
| SCHEMBL21771094 | 0.83 | S1PR1 (0.57) | MAPTS1PR1NPC1PKMRAB9A | |
| SCHEMBL21273246 | 0.81 | S1PR1 (0.52) | MAPTS1PR1NPC1PKMRAB9A | |
| SCHEMBL21771256 | 0.80 | S1PR1 (0.55) | MAPTS1PR1NPC1PKMRAB9A | |
| SCHEMBL21282152 | 0.79 | MAPT (0.47) | MAPTS1PR1APPPKMSMN1; SMN2 | |
| SCHEMBL21282219 | 0.78 | RAB9A (0.48) | MAPTS1PR1NPC1PKMRAB9A | |
| SCHEMBL21282172 | 0.75 | NPC1 (0.61) | MAPTS1PR1NPC1PKMRAB9A | |
| SCHEMBL21282179 | 0.73 | NPC1 (0.64) | MAPTNPC1PKMRAB9AGRM5 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-12012394-B2 | Alpha-synuclein ligands | WASHINGTON UNIVERSITY (US) | 2024-06-18 | — | — | US | disclosed |
| US-20190256492-A1 | ALPHA-SYNUCLEIN LIGANDS | WASHINGTON UNIVERSITY (US) | 2019-08-22 | — | — | US | disclosed |
| US-20190256492-A1 | ALPHA-SYNUCLEIN LIGANDS | WASHINGTON UNIVERSITY (US) | 2019-08-22 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20190256492-A1 | ALPHA-SYNUCLEIN LIGANDS | SNCA, PARK7, LRRK2 | MAPT 58/4885S1PR1 1435/4885APP 161/4885 |
| US-12012394-B2 | Alpha-synuclein ligands | SNCA, PARK7, LRRK2 | MAPT 58/4885S1PR1 1435/4885APP 161/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.